Published Date：Nov. 2020
Industry：Service & Software
Pages：106 Table Number：125
Single User Price：￥3650.00
Enterprise User Price：￥5600.00
Summary As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%. Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States. In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter. Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970. Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. XYZResearch published a report for global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market in this environment. In terms of revenue, this research report indicated that the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments. The AstraZenenca aims at producing XX Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in 2020, with XX % production to take place in global market, Astellas Pharmaceuticals accounts for a volume share of XX %. Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by XYZResearch Include China EU USA Japan India Southeast Asia South America Competitive Analysis; Who are the Major Players in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market? AstraZenenca Astellas Pharmaceuticals Salix Pharmaceuticals Ltd GlaxoSmithKline Actavis Pfizer ... Major Type of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Covered in XYZResearch report: Preface Eluxadoline Alosetron Rifaximin Loperamide Diphenoxylate + Atropine Dicyclomine and Hyoscyamine Application Segments Covered in XYZResearch Market Hospitals Clinics Others For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate 1 Market Scope 1.1 Product Details and Introduction 1.1.1 Preface -Product Introduction and Major Manufacturers 1.1.2 Eluxadoline -Product Introduction and Major Manufacturers 1.1.3 Alosetron -Product Introduction and Major Manufacturers 1.1.4 Rifaximin -Product Introduction and Major Manufacturers 1.1.5 Loperamide -Product Introduction and Major Manufacturers 1.1.6 Diphenoxylate + Atropine -Product Introduction and Major Manufacturers 1.1.7 Dicyclomine and Hyoscyamine -Product Introduction and Major Manufacturers 1.2 Market Snapshot 1.2.1 Major Companies Overview 1.2.2 Market Concentration 1.2.3 Six-Year Compound Annual Growth Rate (CAGR) 2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Assessment, by Segmentation 2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026) 2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026) 2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026) 3 Regional Market Analysis 3.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market 3.1.1 Top Companies leading Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Development in China (2015-2020) 3.1.2 Sales Value of Major Company in China Market (2015-2020) 3.1.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit), by Type (2019-2020) 3.1.4 Sales in China Market, by Type (2015-2026) 3.2 EU Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market 3.2.1 Top Companies leading Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Development in EU (2015-2020) 3.2.2 Sales Value of Major Company in EU Market (2015-2020) 3.2.3 EU Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit), by Type (2019-2020) 3.2.4 Sales in EU Market, by Type (2015-2026) 3.3 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market 3.3.1 Top Companies leading Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Development in USA (2015-2020) 3.3.2 Sales Value of Major Company in USA Market (2015-2020) 3.3.3 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit), by Type (2019-2020) 3.3.4 Sales in USA Market, by Type (2015-2026) 3.4 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market 3.4.1 Top Companies leading Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Development in Japan (2015-2020) 3.4.2 Sales Value of Major Company in Japan Market (2015-2020) 3.4.3 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit), by Type (2019-2020) 3.4.4 Sales in Japan Market, by Type (2015-2026) 3.5 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market 3.5.1 Top Companies leading Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Development in India (2015-2020) 3.5.2 Sales Value of Major Company in India Market (2015-2020) 3.5.3 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit), by Type (2019-2020) 3.5.4 Sales in India Market, by Type (2015-2026) 3.6 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market 3.6.1 Top Companies leading Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Development in Southeast Asia (2015-2020) 3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020) 3.6.3 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit), by Type (2019-2020) 3.6.4 Sales in Southeast Asia Market, by Type (2015-2026) 3.7 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market 3.7.1 Top Companies leading Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Development in South America (2015-2020) 3.7.2 Sales Value of Major Company in South America Market (2015-2020) 3.7.3 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit), by Type (2019-2020) 3.7.4 Sales in South America Market, by Type (2015-2026) 4 Value Chain (Impact of COVID-19) 4.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Chain Analysis 4.1.1 Upstream 4.1.2 Downstream 4.2 COVID-19 Impact on Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry 4.2.1 Industrial Policy Issued Under the Epidemic Situation 4.3 Cost-Under the Epidemic Situation 4.3.1 Cost of Raw Material 4.4 Channel Analysis 4.4.1 Distribution Channel-Under the Epidemic Situation 4.4.2 Distributors 5 Regional Market Forecast (2021-2026) 5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2026) 5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value and Growth Rate (2021-2026) 6 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Competitive Analysis 6.1 AstraZenenca 6.1.1 AstraZenenca Company Profiles 6.1.2 AstraZenenca Product Introduction 6.1.3 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Revenue (2015-2020) 6.1.4 SWOT Analysis 6.2 Astellas Pharmaceuticals 6.2.1 Astellas Pharmaceuticals Company Profiles 6.2.2 Astellas Pharmaceuticals Product Introduction 6.2.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Revenue (2015-2020) 6.2.4 SWOT Analysis 6.3 Salix Pharmaceuticals Ltd 6.3.1 Salix Pharmaceuticals Ltd Company Profiles 6.3.2 Salix Pharmaceuticals Ltd Product Introduction 6.3.3 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Revenue (2015-2020) 6.3.4 SWOT Analysis 6.4 GlaxoSmithKline 6.4.1 GlaxoSmithKline Company Profiles 6.4.2 GlaxoSmithKline Product Introduction 6.4.3 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Revenue (2015-2020) 6.4.4 SWOT Analysis 6.5 Actavis 6.5.1 Actavis Company Profiles 6.5.2 Actavis Product Introduction 6.5.3 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Revenue (2015-2020) 6.5.4 SWOT Analysis 6.6 Pfizer 6.6.1 Pfizer Company Profiles 6.6.2 Pfizer Product Introduction 6.6.3 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production, Revenue (2015-2020) 6.6.4 SWOT Analysis 7 Conclusion
List of Tables and Figures Figure Product Introduction Table Production (K Units) and Revenue (Million USD) of Major Players (2015-2020) Figure Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Market Share of Top 5 Players Table CAGR of Major Market (2021-2026) Table CAGR in Terms of Production of Each Type (2015-2026) Table CAGR in Terms of Production of Each Application (2015-2026) Table Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Unit) by Type (2015-2026) Figure Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Unit) and Growth Rate (2015-2026) Figure Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share (%) by Type (2019 -2020) Table Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (Million USD) by Type (2015-2026) Figure Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (Million USD) and Growth Rate (2015-2026) Figure Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Market Share (%) by Type (2019-2020) Table Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Unit) by Application (2015-2026) Table China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Unit) of Major Company (2015-2020) Table China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share of Major Company (2015-2020) Table China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (Million USD) of Major Company (2015-2020) Figure China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (Million USD) and Growth Rate (2015-2020) Table China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share of Major Company (2015-2020) Table China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit), by Type (2019-2020) Table China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Unit) by Type (2015-2026) Figure China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Unit) by Type (2015-2026) Table EU Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Unit) of Major Company (2015-2020) Table EU Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share of Major Company (2015-2020) Table EU Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (Million USD) of Major Company (2015-2020) Figure EU Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (Million USD) and Growth Rate (2015-2020) Table EU Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share of Major Company (2015-2020) Table EU Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit), by Type (2019-2020) Table EU Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Unit) by Type (2015-2026) Figure EU Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Unit) by Type (2015-2026) Table USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Unit) of Major Company (2015-2020) Table USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share of Major Company (2015-2020) Table USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (Million USD) of Major Company (2015-2020) Figure USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (Million USD) and Growth Rate (2015-2020) Table USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share of Major Company (2015-2020) Table USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit), by Type (2019-2020) Table USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Unit) by Type (2015-2026) Figure USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Unit) by Type (2015-2026) Table Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Unit) of Major Company (2015-2020) Table Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share of Major Company (2015-2020) Table Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (Million USD) of Major Company (2015-2020) Figure Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (Million USD) and Growth Rate (2015-2020) Table Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share of Major Company (2015-2020) Table Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit), by Type (2019-2020) Table Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Unit) by Type (2015-2026) Figure Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Unit) by Type (2015-2026) Table India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Unit) of Major Company (2015-2020) Table India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share of Major Company (2015-2020) Table India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (Million USD) of Major Company (2015-2020) Figure India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (Million USD) and Growth Rate (2015-2020) Table India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share of Major Company (2015-2020) Table India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit), by Type (2019-2020) Table India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Unit) by Type (2015-2026) Figure India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Unit) by Type (2015-2026) Table Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Unit) of Major Company (2015-2020) Table Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share of Major Company (2015-2020) Table Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (Million USD) of Major Company (2015-2020) Figure Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (Million USD) and Growth Rate (2015-2020) Table Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share of Major Company (2015-2020) Table Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit), by Type (2019-2020) Table Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Unit) by Type (2015-2026) Figure Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Unit) by Type (2015-2026) Table South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Unit) of Major Company (2015-2020) Table South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share of Major Company (2015-2020) Table South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (Million USD) of Major Company (2015-2020) Figure South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (Million USD) and Growth Rate (2015-2020) Table South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value Share of Major Company (2015-2020) Table South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit), by Type (2019-2020) Table South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Unit) by Type (2015-2026) Figure South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Unit) by Type (2015-2026) Figure Value Chain Structure of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Table Value Chain Table Key Suppliers of Raw Material/Components Table Key Downstream Customer in Each Application Field Table Industry News List of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Figure Cost Structure of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in 2020 Table Distributors/Traders List Table Regional Market Sales (K Unit) (2021-2026) Table Regional Market Sales Share (2021-2026) Figure Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Unit), Growth Rate & Market Share (2021-2026) Table Regional Market Sales Value (Million USD) (2021-2026) Table Regional Market Sales Value Share (2021-2026) Figure Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Value (Million USD), Growth Rate & Market Share (2021-2026) Table AstraZenenca Profiles Table AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction Table AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure AstraZenenca SWOT Analysis Table Astellas Pharmaceuticals Profiles Table Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction Table Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Astellas Pharmaceuticals SWOT Analysis Table Salix Pharmaceuticals Ltd Profiles Table Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction Table Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Salix Pharmaceuticals Ltd SWOT Analysis Table GlaxoSmithKline Profiles Table GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction Table GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure GlaxoSmithKline SWOT Analysis Table Actavis Profiles Table Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction Table Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Actavis SWOT Analysis Table Pfizer Profiles Table Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction Table Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020)
